文献速递心外重症与机械循环支持

LVAD植入合并三尖瓣反流手术的随机试验晚期随访

Late follow-up for a randomized trial of surgical treatment of tricuspid valve regurgitation in patients undergoing left ventricular assist device implantation.
PubMed 文献 · J Thorac Cardiovasc Surg · 2024-09-21

该随机试验纳入71例术前中重度三尖瓣反流(TR)拟行持久LVAD植入的患者,随机分为单纯LVAD组(34例)与同期三尖瓣手术(TVS)组(37例),随访至少12个月。12个月时两组中重度右心衰(RHF)发生率分别为无TVS组50.0%与TVS组51.4%,TR严重程度无显著差异,因无TVS组TR随时间改善。

要点

  • 12个月中重度RHF发生率:无TVS组50.0% vs TVS组51.4%。
  • 12个月两组TR严重程度无显著差异,与无TVS组TR改善有关。
  • RHF死亡:TVS组5.4% vs 无TVS组8.8%。

核心结论

  • 在术前显著TR患者中,单纯LVAD植入组的TR严重程度随时间改善,12个月时两组TR严重程度无显著差异,这可能解释晚期临床或功能参数无差异。

研究设计与样本

  • 随机对照试验,术前超声示中重度TR患者n=71,随机分为单纯LVAD植入组(无TVS组,n=34)与同期TVS组(n=37)。
  • 随机按术前右心室功能障碍分层,术后随访至少12个月,RHF由裁定委员会按Interagency Registry for Mechanically Assisted Circulatory Support标准判定。

主要发现

  • 12个月时中重度RHF发生率:无TVS组50.0% vs TVS组51.4%。
  • 术后6至12个月无患者新发RHF。
  • RHF死亡:TVS组5.4% vs 无TVS组8.8%。
  • 12个月时两组TR严重程度无显著差异,归因于无TVS组TR严重程度改善。
  • 12个月以上心肺运动试验显示两组峰值氧耗量无显著差异。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We previously reported that concurrent tricuspid valve surgery (TVS) was not associated with a lower incidence of early right heart failure (RHF) in patients undergoing durable left ventricular assist device (LVAD) implantation. This follow-up analysis aimed to further define the clinical impact of concurrent TVS after 2 months of follow-up. METHODS: Patients with moderate or severe tricuspid regurgitation (TR) on preoperative echocardiography (n = 71) were randomized to LVAD implantation either alone (no TVS group; n = 34) or with concurrent TVS (TVS group; n = 37). Randomization was stratified by preoperative right ventricular dysfunction. The patients were followed for at least 12 months after surgery. The incidence of RHF was determined by an adjudication committee using Interagency Registry for Mechanically Assisted Circulatory Support criteria. Functional studies and repeat echocardiography were performed at 12 months. RESULTS: Demographics were similar in the 2 study arms. At 12 months, the rate of moderate or severe RHF was 50.0% in the no TVS arm versus 51.4% in the TVS arm. No patients developed RHF between 6 and 12 months following the procedure. Death from RHF was 5.4% in the TVS arm versus 8.8% in the no TVS arm. At 12 months, there was no significant difference in TR severity between the 2 arms, owing to improvement in TR severity in the no TVS arm. Cardiopulmonary exercise testing at 12+ months revealed no significant between-group difference in peak oxygen consumption. CONCLUSIONS: In patients with significant preimplantation TR, the severity of TR improved over time in the no TVS arm with LVAD implantation alone. By 12 months, there was no significant difference in TR severity between the 2 arms. This may account for the lack of difference in late clinical or functional parameters.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Mendiola Pla M, Russell SD, Milano CA, et al. Late follow-up for a randomized trial of surgical treatment of tricuspid valve regurgitation in patients undergoing left ventricular assist device implantation. J Thorac Cardiovasc Surg. 2024. PMID: 39313112. doi:10.1016/j.jtcvs.2024.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。